Returning guest, Dr. Michael Korn, Chief Medical Officer at Caris® Life Sciences discusses new data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from a study that supports that the treatment of certain ovarian cancer patients with KRAS-mutated epithelial ovarian carcinomas (EOC) may benefit from targeted therapies designed to inhibit KRAS gene response. He also talks about additional presentations that reveal the potential impact of precision medicine using Caris’ industry-leading technology.
Dr. Korn joined Caris Life Sciences in September 2017 as Chief Medical Officer. In this role, Dr. Korn guides Caris’ research efforts and clinical strategies for innovative precision medicine tools and tumor profiling services. His executive oversight responsibilities include medical affairs, evidence cultivation and the Caris Research Institute™, which has produced more than 150 posters/presentations at major medical conferences and over 50 peer-reviewed publications since 2014. Dr. Korn has an extensive career in cancer research and clinical oncology. He has long-standing experience in molecular tumor profiling and integration of these techniques in clinical practice. He has authored more than 45 peer-reviewed publications and his research on signal transduction and systems biology of cancer has been funded by the NIH and DoD since 2003. Dr. Korn serves on the Esophago-Gastric Task Force of the NCI GI Steering Committee, and is a member of the National Comprehensive Cancer Network (NCCN) Esophageal and Gastric Cancer Panel. Dr. Korn is also Professor of Medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF). He founded the Molecular Oncology Initiative at UCSF’s Helen Diller Family Comprehensive Cancer Center (HDFCCC), and initiated and chaired the UCSF Molecular Tumor Board, which is a cross-disciplinary platform supporting clinical decision making based on Next-Generation Sequencing results.Dr. Korn received his M.D. from Philipps University of Marburg, Germany. He performed his internal medicine and gastroenterology training at Ev. Krankenhaus Dinslaken, Germany, and his medical oncology training from the West German Cancer Center, University of Essen, Germany. He completed post-doctoral training with Dr. Frank McCormick at UCSF.